Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

CRISPR Therapeutics is a leading biotech company, currently developing gene-editing techniques to cure hereditary diseases with promising projects underway. The company's Q1 2023 revenue was 100M USD ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics (NASDAQ:CRSP) revealed 9 unusual trades. Delving into the details, ...

According to Benzinga Pro, CRISPR Therapeutics AG's peer group average for short interest as a percentage of float is 14.28%, which means the company has more short interest than most of its peers.

CRISPR Therapeutics is a gene therapy and gene editing company focused on developing gene-based medicines using CRISPR and Cas9 technologies. The company recently gained approval for Casgevy, a cure ...

Labroots invites you to the 8th Annual CRISPR Virtual Event Series 2025, taking place on October 22nd, 2025! This event will explore the expanding frontier of CRISPR technology, with sessions covering ...